Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta‐analysis

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

2005 • 4,040 citations

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

2006 • 2,850 citations

Epidemiology and Risk Factors of Urothelial Bladder Cancer

2012 • 1,914 citations

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

2009 • 1,337 citations

Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus

2007 • 1,240 citations

The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey

2007 • 939 citations

When can odds ratios mislead?

1998 • 916 citations

Much ado about nothing: a comparison of the performance of meta‐analytical methods with rare events

2006 • 873 citations

Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes

2008 • 836 citations

Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone

2011 • 622 citations

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

2008 • 529 citations

Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone

2010 • 502 citations

Bladder Cancer in 2010: How Far have We Come?

2010 • 326 citations

Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study

2012 • 273 citations

The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study

2012 • 264 citations

Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting

2011 • 239 citations

Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes

2009 • 220 citations

Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus

2011 • 175 citations

Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials

2010 • 165 citations

Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis

2012 • 151 citations

Pioglitazone and risk of bladder cancer: a meta‐analysis of controlled studies

2013 • 135 citations

Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan

2011 • 127 citations

Pioglitazone and Bladder Cancer

2011 • 121 citations

Association Between Longer Therapy With Thiazolidinediones and Risk of Bladder Cancer: A Cohort Study

2012 • 108 citations

Pioglitazone and bladder cancer: a propensity score matched cohort study

2012 • 86 citations

Effects of Pioglitazone, a Peroxisome Proliferator–Activated Receptor Gamma Agonist, on the Urine and Urothelium of the Rat

2009 • 78 citations

Rosiglitazone, a PPAR gamma agonist: Potent promoter of hydroxybutyl(butyl)nitrosamine‐induced urinary bladder cancers

2008 • 73 citations

Effects of PPARγ and Combined Agonists on the Urinary Tract of Rats and Other Species

2005 • 68 citations

Examining the safety of PPAR agonists – current trends and future prospects

2012 • 68 citations

Risk of Bladder Cancer in Diabetic Patients Treated with Rosiglitazone or Pioglitazone: A Nested Case–Control Study

2013 • 67 citations

Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: A meta-analysis

2012 • 63 citations

Liver Safety in Patients with Type 2 Diabetes Treated with Pioglitazone

2009 • 52 citations

Urothelial Carcinogenesis in the Urinary Bladder of Rats Treated with Naveglitazar, a γ-dominant PPAR α/γ Agonist: Lack of Evidence for Urolithiasis as an Inciting Event

2008 • 39 citations

Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats

2011 • 35 citations

The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone

2012 • 34 citations

Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes

2012 • 33 citations

Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn?

2013 • 29 citations

Neoplastic and Non-neoplastic Changes in F-344 Rats Treated with Naveglitazar, a γ-Dominant PPAR α/γ Agonist

2009 • 23 citations

More on influenza vaccine in young children.

2012 • 22 citations

Pioglitazone – Do we really need it to manage type 2 diabetes?

2013 • 22 citations

Rosiglitazone is not associated with an increased risk of bladder cancer

2013 • 19 citations

FDA panel advises easing restrictions on rosiglitazone

2013 • 16 citations

Pioglitazone—Do we really need it to manage type 2 diabetes?

2013 • 14 citations

Flip flop policy over pioglitazone licence causes media storm in India

2013 • 3 citations